All In MedTech

Device Trial Radar · NCT03303612

Clinical Monitoring Strategy Versus Electrophysiology-guided Algorithmic Approach With a New LBBB After TAVI

Comparison of a Clinical Monitoring Strategy Versus Electrophysiology-guided Algorithmic Approach in Patients With a New Left Bundle Branch Block After Transcatheter Aortic Valve Implantation (TAVI) a Bayesian Randomized Trial (COME-TAVI)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Oct 15, 2017

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Montreal Heart InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 6, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary hypothesis of the proposed study is that an electrophysiology-based algorithmic approach is superior to standard clinical follow-up with 30-day monitoring in reducing the combined endpoint of syncope, hospitalization, and death in patients in patients with new of left bundle branch block following transcatheter aortic valve implantation (TAVI).

Conditions

  • Left Bundle-Branch Block
  • Aortic Valve Stenosis

Interventions

  • Pacemaker implantDevice

    Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.

  • Transcutaneous cardiac monitorDevice

    Transcutaneous cardiac patches will allow continuous electrocardiographic monitoring for a 30-day period. For the first randomized patients at the Montreal Heart Institute, Icentia was used and then was changed to a m-Health® device which allows continuous cardiac monitoring. The PocketECG from m-Health® is attached to 3 electrodes on the chest and contains a SIM card that transmits to a server located in Burlington, Ontario .The COME-TAVI coordinating center and the associated site will be informed rapidly of any events that occur . These events include: Ventricular fibrillation; Sustained ventricular tachycardia Any RR interval \>5 sec; Third-degree AV block or Mobitz 2 AV block;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with cardiovascular hospitalization, and/or syncope, and/or death after TAVI.Time frame: 12 months

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Mazankowski Alberta Heart Institute

    Edmonton, Alberta, Canada · Recruiting

  • New Brunswick Heart Center

    Saint John, New Brunswick, Canada · Not yet recruiting

  • QEII Health Sciences Center

    Halifax, Nova Scotia, Canada · Recruiting

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.